ClinicalTrials.gg
Active, not recruitingNCT05655013Updated Oct 2, 2025

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)

A Phase 4 interventional study of Zoledronate and Placebo in Osteoporosis, Postmenopausal, sponsored by Aarhus University Hospital. Active, not recruiting at 1 site in Denmark. Open to female participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Aarhus University Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
40 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal — none open to participants now, 1 under way, none of them phase 3. Zoledronic Acid · Osteoporosis, Postmenopausal.

Planned enrollment
5th of 10
200 · median 195
Started
2023
the only one that year
Phase 4
5 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Aarhus University Hospital

Among the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is one of 5 in phase 4, and was the 10th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

About Zoledronic Acid

Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 40 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal as a file.
02

Study summary

The aims of ZOLARMAB2 are fourfold. First, the investigators want to investigate if multiple infusions of zoledronate can prevent the rebound activation of bone turnover and the subsequent bone loss in patients previously treated with denosumab and if there is difference between infusing zoledronate at fixed time-points after the last injection of denosumab or when bone turnover is increased.

Second, the investigators want to investigate if bone loss will resume after controlling the rebound activation of bone turnover during the first year after denosumab discontinuation and if this can be prevented by yearly infusions of zoledronate.

Third, the investigators want to investigate the underlying pathophysiological mechanisms by investigating biochemical markers, osteoclast and osteoblast activation signals in the bone and bone marrow, and the pool of preosteoclasts/mature osteoclasts before and after treatment with zoledronate.

Fourth, the investigators want to investigate the effect of denosumab discontinuation on muscle mass and muscle strength and on insulin sensitivity.

Read the detailed description

This study has two parts. The first part (year 1) is a randomized open label, interventional study in 200 postmenopausal women investigating if treatment with zoledronate prevents bone loss after denosumab treatment. Zoledronate will be administered as an infusion six months after the last injection of denosumab followed by zoledronate infusions 3 and 6 months thereafter (groups 3+4) or followed by zoledronate infusions when bone turnover is increased (p-carboxy-terminal collagen crosslinks (p-CTX) > 0.4 ug/l which corresponds to the upper 50 % of the normal range for premenopausal women) (groups 1+2). Fifty patients will be randomised to each group. The patients in groups 1+2 will be monitored and if (p-CTX) is above 0.4 ug/l at month 3 or 6 zoledronate will be administered. If a patient in groups 3+4 experiences an osteoporotic clinical vertebral or hip fracture, zoledronate will be administered irrespective of p-CTX.

The second part is a 2-year randomised, double-blind, interventional study in the women completing part 1. Patients in groups 1+3 will receive yearly infusions of zoledronate 5 mg and patients in groups 2+4 will receive yearly infusions of placebo.

The patients will be monitored with DXA of the hip and spine 3, 6, 12, 24, and 36 months after baseline. Zoledronate will be administered to the patients allocated to the placebo group during phase 2 if BMD decreases more than 5% at the lumbar spine, total hip or femoral neck after months 12.

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (postmenopausal for at least two years)
  • Age ≥ 40 years
  • Treatment for at least two years with denosumab
  • Last denosumab injection less than six months ago
  • At least 2 lumbar vertebrae that can be evaluated by DXA

Exclusion criteria

Exclusion Criteria:

  • Low-energy vertebral fracture within the last ten years
  • Multiple low-energy vertebral fractures (> 3) at any time
  • Low-energy hip fracture within the last 12 months
  • BMD T-score \< -2.5 (lumbar spine, total hip or femoral neck)
  • Zoledronate treatment for more than three years prior to denosumab treatment within the last ten years
  • Alendronate treatment for more than three years prior to denosumab treatment within the last five years or for more than five years within the last 10 the years
  • Treatment with other bisphosphonates (risedronate, ibandronate) for more than three years prior to denosumab treatment within the last five years
  • Diabetes Mellitus
  • Ongoing treatment with systemic
  • Metabolic bone disease (for example osteogenesis imperfecta, Paget's disease of bone)
  • Hormone replacement therapy
  • Active cancer within the last 5 years with the exception of basal cell skin cancer
  • Estimated (eGFR) ≤ 35 mL/min
  • for zoledronate according to the SPC
  • Unable to read and understand Danish
  • Immobility
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    First part (year 1): groups 1+2

    Zoledronate will be administered as an infusion six months after the last injection of denosumab followed by zoledronate infusions 3 and 6 months thereafter

    Drug: Zoledronate

  • Active comparator
    First part (year 1): groups 3+4

    Zoledronate will be administered as an infusion six months after the last injection of denosumab followed by zoledronate infusions when bone turnover is increased (s-carboxy-terminal collagen crosslinks (p-CTX) \> 0.4 ug/l which corresponds to the upper 50 % of the normal range for premenopausal women).

    Drug: Zoledronate

  • Active comparator
    Second part (year 2-3): groups 1+3

    Patients will receive yearly infusions of zoledronate 5 mg

    Drug: Zoledronate

  • Placebo comparator
    Second part (year 2-3): groups 2+4

    Patients will receive yearly infusions of placebo.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in lumbar spine bone mineral density (BMD)

    Change in lumbar spine BMD after 12 and 36 months.

    Time frame: After 12 and 36 months.

  2. The proportion of patients who fails to maintain bone mineral density (BMD)

    The proportion of patients (%) with significant decrease in BMD (≥ 3 % BMD loss at the lumbar spine or ≥ 5 % BMD loss at the femoral neck or total hip) after 12 months.

    Time frame: After 12 months.

Secondary outcomes

  1. Changes in total hip and femoral neck bone mineral density (BMD)

    Changes in total hip and femoral neck BMD after 12 and 36 months.

    Time frame: After 12 and 36 months.

  2. Changes in trabecular bone volume fraction (bone volume/tissue volume, BV/TV) and cortical porosity measured by high-resolution peripheral quantitative computed tomography (HR-pQCT)

    Mean percent change in trabecular bone volume fraction and cortical porosity measured by HR-pQCT at the radius and tibia after 12 and 36 months.

    Time frame: After 12 and 36 months.

  3. Changes in carboxy-terminal collagen crosslinks (CTX) and procollagen type I N-terminal propeptide (PINP)

    Changes in CTX and PINP after 3, 6, 12, 24 and 36 months.

    Time frame: After 3, 6, 12, 24 and 36 months.

  4. Morphometric vertebral fractures

    Morphometric vertebral fractures assessed by vertebral fracture assessment (VFA) after 12 and 36 months or by spinal x-ray if clinical suspicion of vertebral fracture.

    Time frame: After 12 and 36 months.

  5. Serum RANKL/OPG, tartrate-resistant acid phosphatase type 5b (TRAcP-5b), sclerostin and Dickkopf-1 (Dkk-1)

    Serum RANKL/OPG, tartrate-resistant acid phosphatase type 5b (TRAcP-5b), sclerostin and Dickkopf-1 (Dkk-1) at 0, 1, 3, 6 and 12 months

    Time frame: Baseline and after 1, 3, 6 and 12 months

  6. Molecular bone histology

    Molecular bone histology of accumulating osteoclast activation sites and pre-osteoclasts as well as single-nucleus transcriptomics on jamshidi biopsies at baseline in a total of 100 patients from groups 1 and 2 and in up to 15 participants in groups 1 and 2 at month 3 with a strong rebound response (p-CTX \> 0.6 ug/l).

    Time frame: Baseline and after 3 months

  7. Osteoclasts

    Osteoclasts differentiation, fusion, function, and response to zoledronate in cultures derived from peripheral blood at baseline from groups 1 and 2. 30 patients will be recruited from each group, hence 60 patients.

    Time frame: Baseline

  8. Epigenetic marker analysis

    Epigenetic marker analysis with special focus on genes involved in osteoclast activation, differentiation, fusion, function and response to ZOL. Samples collected at baseline from all participants.

    Time frame: Baseline

  9. Muscle mass and muscle strength

    Muscle mass assessed by whole-body DXA and muscle strength assessed by handgrip strength and muscle strength over the knee and elbow joints. A total of 100 patients from groups 1 and 2 will be investigated at baseline month 3 and 12.

    Time frame: Baseline and after 3 and 12 months

  10. Insulin sensitivity

    Insulin sensitivity assessed by Hb1Ac, HOMA-IR, OGTT and advanced glycation end products (AGEs).

    Time frame: Baseline and after 3, 12, 18, 24 and 36 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Feb 2027, 44 months after the start.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 16, 2022
StartActual
May 10, 2023
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05655013
Responsible party
Anne Sophie Sølling (MD, PhD, Department of Endocrinology and Internal Medicine, Aarhus University Hospital) — Principal investigator
First posted
Dec 16, 2022
Start date
May 10, 2023
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Oct 2, 2025

Study contacts

Bente Langdahl, MD, Professor, DMSc, PhD
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zoledronic Acid

Start the discussion